BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 2021105)

  • 1. Mycosis fungoides: cutaneous T-cell lymphoma.
    Zaim MT; Grinkemeyer MD
    Am Fam Physician; 1991 May; 43(5):1703-7. PubMed ID: 2021105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modified staging classification for cutaneous T-cell lymphoma.
    Kashani-Sabet M; McMillan A; Zackheim HS
    J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis.
    Smith BD; Wilson LD
    Oncology (Williston Park); 2003 Sep; 17(9):1281-8. PubMed ID: 14569854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycosis fungoides and the Sézary syndrome.
    Kim YH; Hoppe RT
    Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
    Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
    Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile mycosis fungoides treated with bexarotene and PUVA.
    Rodríguez-Vázquez M; García-Arpa M; González-García J
    Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of cutaneous T-cell lymphoma.
    Abel EA
    Dermatol Clin; 1985 Oct; 3(4):647-64. PubMed ID: 2878755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
    Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
    J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mycosis fungoides and Sézary syndrome. A retrospective study of 60 patients with correlation between histologic classification and survival time].
    Hödl S
    Z Hautkr; 1986 Jul; 61(14):993-1013. PubMed ID: 3751216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
    Hoppe RT; Wood GS; Abel EA
    Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous T-cell lymphoma.
    Lansigan F; Choi J; Foss FM
    Hematol Oncol Clin North Am; 2008 Oct; 22(5):979-96, x. PubMed ID: 18954747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective 5-year review of 131 patients with mycosis fungoides and Sézary syndrome seen at the National Skin Centre, Singapore.
    Tan ES; Tang MB; Tan SH
    Australas J Dermatol; 2006 Nov; 47(4):248-52. PubMed ID: 17034466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome.
    Klemke CD; Mansmann U; Poenitz N; Dippel E; Goerdt S
    Br J Dermatol; 2005 Jul; 153(1):118-24. PubMed ID: 16029336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
    Thomas BR; Whittaker S
    Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implication of the ras and myc oncoproteins in the pathogenesis of mycosis fungoides.
    Tosca A; Linardopoulos S; Malliri A; Hatziolou E; Nicolaidou A; Spandidos DA
    Anticancer Res; 1991; 11(4):1433-8. PubMed ID: 1746900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycosis fungoides--a review of the management of 28 patients and of the recent literature.
    Lenane P; Powell FC; O'Keane C; Dervan P; O'Sullivan D; Bourke E; O'Loughlin S
    Int J Dermatol; 2007 Jan; 46(1):19-26. PubMed ID: 17214715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
    Meissner K; Löning T; Rehpenning W
    Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.